Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Berberine, a compound from rhizome coptidis, is traditionally used to treat gastrointestinal infections, such as bacterial diarrhoea. Recently, berberine was shown to have hypoglycaemic and hypolipidaemic effects. We investigated the mechanisms by which berberine regulates hepatic lipid metabolism and energy expenditure in mice. Experimental Approach: Liver‐specific SIRT1 knockout mice and their wild‐type littermates were fed a high‐fat, high‐sucrose (HFHS) diet and treated with berberine by i.p. injection for five weeks. Mouse primary hepatocytes and human HepG2 cells were treated with berberine and then subjected to immunoblotting analysis and Oil Red O staining. Key Results: Berberine attenuated hepatic steatosis and controlled energy balance in mice by inducing autophagy and FGF21. These beneficial effects of berberine on autophagy and hepatic steatosis were abolished by a deficiency of the nutrient sensor SIRT1 in the liver of HFHS diet‐fed obese mice and in mouse primary hepatocytes. SIRT1 is essential for berberine to potentiate autophagy and inhibit lipid storage in mouse livers in response to fasting. Mechanistically, the berberine stimulates SIRT1 deacetylation activity and induces autophagy in an autophagy protein 5‐dependent manner. Moreover, the administration of berberine was shown to promote hepatic gene expression and circulating levels of FGF21 and ketone bodies in mice in a SIRT1‐dependent manner. Conclusions and Implications: Berberine acts in the liver to regulate lipid utilization and maintain whole‐body energy metabolism by mediating autophagy and FGF21 activation. Hence, it has therapeutic potential for treating metabolic defects under nutritional overload, such as fatty liver diseases, type 2 diabetes and obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autophagy in the Pathogenesis of Disease
Levine, B., & Kroemer, G. (2008) · Cell · doi:10.1016/j.cell.2007.12.018 · Cited by 7,069
Autophagy fights disease through cellular self-digestion
Mizushima, N., Levine, B., Cuervo, A. M., & Klionsky, D. J. (2008) · Nature · doi:10.1038/nature06639 · Cited by 6,452 · cited 1×
“Autophagy is a cellular quality control pathway that degrades cytoplasmic contents in the lysosomes (Levine and Kroemer, 2008; Mizushima et al., 2008).”
BackgroundResveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Autophagy regulates lipid metabolism
Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A. M., & Czaja, M. J. (2009) · Nature · doi:10.1038/nature07976 · Cited by 3,975
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160 · cited 1×
“Strikingly, the reduction of lipid accumulation caused by berberine was largely blocked by treatment with the specific SIRT1 inhibitor EX527 (Rodgers et al., 2005), as assessed by triglyceride levels (Figure 4C) and Oil Red O staining (Figure 4D).”
BackgroundFGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089 · cited 1×
“The liver is the central metabolic organ that regulates lipid homeostasis such as de novo lipogenesis, fatty acid βoxidation in mitochondria, lipoprotein uptake and secretion in response to nutritional and hormonal signals (Cohen et al., 2011).”
BackgroundPPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016 · cited 2×
“, 2016), which is similar to the observations obtained in diabetic mice, where it was found to act as an insulin sensitizer and lower blood glucose levels (Ahmadian et al., 2013; Suh et al., 2014).”
BackgroundResultAnimal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
Cited by
Madeo, F., Carmona-Gutierrez, D., Hofer, S. J., & Kroemer, G. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.018 · Cited by 630
Biological properties and clinical applications of berberine
Song, D., Hao, J., & Fan, D. (2020) · Frontiers of Medicine · doi:10.1007/s11684-019-0724-6 · Cited by 496
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics
Feng, X., Sureda, A., Jafari, S., Memariani, Z., Tewari, D., Annunziata, G., Barrea, L., Hassan, S. T. S., Šmejkal, K., Malaník, M., et al. (2019) · Theranostics · doi:10.7150/thno.30787 · Cited by 465
Wang, J., Wang, L., Lou, G.-H., Zeng, H.-R., Hu, J., Huang, Q.-W., Peng, W., & Yang, X.-B. (2019) · Pharmaceutical Biology · doi:10.1080/13880209.2019.1577466 · Cited by 424
Cai, Y., Song, W., Li, J., Jing, Y., Liang, C., Zhang, L., Zhang, X., Zhang, W., Liu, B., An, Y., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2161-3 · Cited by 408
Self-citationThe AMPK pathway in fatty liver disease
Fang, C., Pan, J., Qu, N., Lei, Y., Han, J., Zhang, J., & Han, D. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.970292 · Cited by 364
Zhao, Z.-H., Xin, F.-Z., Xue, Y., Hu, Z., Han, Y., Ma, F., Zhou, D., Liu, X.-L., Cui, A., Liu, Z., et al. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0304-5 · Cited by 347
Self-citationBerberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway
Zhu, X., Bian, H., Wang, L., Sun, X., Xu, X., Yan, H., Xia, M., Chang, X., Lu, Y., Li, Y., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.06.019 · Cited by 273
Self-citationBerberine as a potential autophagy modulator
Mohammadinejad, R., Ahmadi, Z., Tavakol, S., & Ashrafizadeh, M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28325 · Cited by 132
Xu, Y., Yu, T., Ma, G., Zheng, L., Jiang, X., Yang, F., Wang, Z., Li, N., He, Z., Song, X., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.62556 · Cited by 110
Fang, Y., Ji, L., Zhu, C., Xiao, Y., Zhang, J., Lu, J., Yin, J., & Wei, L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.602574 · Cited by 108
Obesity: pathophysiology and therapeutic interventions
Kong, Y., Yang, H., Nie, R., Zhang, X., Zuo, F., Zhang, H., & Nian, X. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00264-9 · Cited by 89
Pharmacokinetics and Pharmacological Activities of Berberine in Diabetes Mellitus Treatment
Han, Y., Xiang, Y., Shi, Y., Tang, X., Pan, L., Gao, J., Bi, R., & Lai, X. (2021) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2021/9987097 · Cited by 51
“mechanisms such as inducing FGF21 production and secretion and promoting white fat browning [48, 72].”
BackgroundSelf-citationAdipose Tissue SIRT1 Regulates Insulin Sensitizing and Anti-Inflammatory Effects of Berberine
Shan, Y., Zhang, S., Gao, B., Liang, S., Zhang, H., Yu, X., Zhao, J., Ye, L., Yang, Q., & Shang, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.591227 · Cited by 49
Wang, Y., Bian, X., Wan, M., Dong, W., Gao, W., Yao, Z., & Guo, C. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-023-00775-8 · Cited by 20
“Then, they were embedded in optimum cutting temperature compound and stained with Oil red O kit according to the manufacturer’s instructions [28].”
MethodCole, L. K., Zhang, M., Chen, L., Sparagna, G. C., Vandel, M., Xiang, B., Dolinsky, V. W., & Hatch, G. M. (2021) · The Journal of Nutrition · doi:10.1093/jn/nxaa408 · Cited by 18
Metadata
- Authors
- Sun, Y., Xia, M., Yan, H., Han, Y., Zhang, F., Hu, Z., Cui, A., Ma, F., Liu, Z., Gong, Q., Chen, X., Gao, J., Bian, H., Tan, Y., Li, Y., & Gao, X.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2017-12-15
- Volume
- 175
- Issue
- 2
- Pages
- 374-387
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2766550174
- Cited by
- 151
- References
- 25
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.